John V. Oyler is Chairman and Co-Founder of Beigene Ltd, and has served as the Chief Executive Officer and a member of the Board of Directors since 2010. From 2005 to 2009, Mr. Oyler served as President and Chief Executive Officer of BioDuro, LLC, a drug discovery outsourcing company, which was acquired by Pharmaceutical Product Development Inc. in 2010. From 2002 to 2004, Mr. Oyler served as Chief Executive Officer of Galenea Corp., a biopharmaceutical company dedicated to the discovery of novel therapies for central nervous system diseases, which initially were developed at Massachusetts Institute of Technology. From 1997 to 2002, Mr. Oyler was a Founder and the President of Telephia, Inc. which was sold to The Nielsen Company in 2007. From 1997 to 1998, Mr. Oyler served as Co-Chief Executive Officer of Genta Incorporated (NASDAQ: GNTA), an oncology‑focused biopharmaceutical company. Mr. Oyler joined the Board of Directors of the Biotechnology Innovation Organization (BIO) in 2019 and is a member of its Health Section Governing Board. He began his career as a management consultant at McKinsey & Company. Mr. Oyler received his B.S. from Massachusetts Institute of Technology and MBA from Stanford University.
GapSummit is the premier, global, intergenerational biotechnology summit that attracts world leaders and the next generation of leaders to substantively discuss pressing challenges facing the bioeconomy and catalyze innovation to address these challenges.
GBR is a not-for-profit that connects biotech think-tanks, industrial leaders and research pioneers to young bio-leaders of tomorrow. GBR is solely led by young passionate and engaged researchers, students and professionals from across the world. GapSummit is GBR’s flagship event to advance its mission of developing and inspiring the next generation of leaders in the global bio-economy.